These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 17091608

  • 1. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
    Voglová J, Maisnar V, Beránek M, Chrobák L.
    Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
    [Abstract] [Full Text] [Related]

  • 2. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 Jan 01; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

  • 9. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT.
    Leukemia; 2005 Jan 01; 19(1):39-43. PubMed ID: 15510207
    [Abstract] [Full Text] [Related]

  • 10. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D.
    Ther Umsch; 2006 Apr 01; 63(4):249-54. PubMed ID: 16689455
    [Abstract] [Full Text] [Related]

  • 11. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H.
    Cancer; 2007 Sep 15; 110(6):1295-302. PubMed ID: 17623836
    [Abstract] [Full Text] [Related]

  • 12. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S, Korean Society of Hematology CML working party.
    Ann Hematol; 2010 Jul 15; 89(7):725-31. PubMed ID: 20179930
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.
    N Engl J Med; 2006 Jun 15; 354(24):2531-41. PubMed ID: 16775234
    [Abstract] [Full Text] [Related]

  • 15. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M.
    N Engl J Med; 2001 Apr 05; 344(14):1038-42. PubMed ID: 11287973
    [Abstract] [Full Text] [Related]

  • 16. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
    Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA.
    Clin Cancer Res; 2003 Jun 05; 9(6):2092-7. PubMed ID: 12796373
    [Abstract] [Full Text] [Related]

  • 17. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
    Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ.
    Blood; 2002 May 15; 99(10):3530-9. PubMed ID: 11986204
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
    Chrobák L, Voglová J.
    Acta Medica (Hradec Kralove); 2003 May 15; 46(3):85-9. PubMed ID: 14677715
    [Abstract] [Full Text] [Related]

  • 19. Initial treatment for patients with CML.
    Goldman JM.
    Hematology Am Soc Hematol Educ Program; 2009 May 15; ():453-60. PubMed ID: 20008231
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.
    Hirose Y, Kiyoi H, Iwai M, Yokozawa T, Ito M, Naoe T.
    Int J Hematol; 2002 Nov 15; 76(4):349-53. PubMed ID: 12463599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.